French Medtech Firm RDS Secures €14m for European Expansion of Remote Patient Monitoring Solution
French medical tech firm RDS has secured €14m in a Series A funding round. The company plans to use the funds to expand its reach in Europe and accelerate development of its MultiSense solution for remote patient monitoring.
RDS' innovative technology has already been trialled in 15 hospitals across France, Belgium, and Germany. The MultiSense solution comprises a wearable patch that tracks six key physiological indicators, connected to a cloud-based platform for continuous remote monitoring.
The funding round was led by the SPI fund, managed by Bpifrance on behalf of the French state, with Critical Path Ventures joining as a first-time investor. Previous investors, including MACSF and Capital Grand Est, also contributed. The global market for vital signs monitoring is projected to reach $15bn this year and grow at an average of 15% annually until 2030, presenting a significant opportunity for RDS.
Professor Jacques Marescaux, a member of RDS' scientific board, believes the MultiSense patch offers an effective solution for faster patient discharge and better vital sign monitoring. With the new funds, RDS aims to launch further clinical trials in Europe and target a US launch in 2028.
RDS, with its €14m Series A funding, is poised to expand its innovative remote patient monitoring solution across Europe. The company's MultiSense patch, already trialled in several hospitals, shows promise in improving patient care and discharge processes.
Read also:
- Abu Dhabi initiative for comprehensive genetic screening, aiming to diagnose over 800 conditions and enhance the health of future generations in the UAE.
- Elderly shingles: Recognizing symptoms, potential problems, and available treatments
- Exploring the Reasons, Purposes, and Enigmas of Hiccups: Delving into Their Origins, Roles, and Unsolved Aspects
- Various forms of cataracts include nuclear, pediatric, traumatic, and additional types
